Welcome to our dedicated page for Radius Recycling news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Recycling stock.
Radius Recycling, Inc. (NASDAQ: RDUS), formerly known as Schnitzer Steel Industries, Inc., stands as a prominent figure in North America's recycling and steel manufacturing industry. Established in 1906 in Portland, Oregon, the company has evolved from a small, one-man scrap metal operation into a major player in the market, boasting a diversified and vertically integrated business model.
Radius Recycling specializes in the recycling of ferrous and nonferrous metals, including end-of-life vehicles, and the manufacture of finished steel products. Their operational network comprises 54 metals recycling facilities, 50 self-service auto parts stores, and an electric arc furnace steel mill. This extensive infrastructure enables Radius to meet global demand efficiently.
Key Business Units:
- Metals Recycling Business: Processes a substantial quantity of recycled ferrous and nonferrous metals, significantly contributing to environmental sustainability and resource conservation.
- Auto Parts Business: Operates 50 retail stores selling serviceable parts from salvaged vehicles, receiving over 4 million annual visits from retail customers.
- Steel Manufacturing Business: Produces a variety of finished steel products, including rebar and wire rod, using eco-friendly electric arc furnace technology.
Despite the challenges posed by tight supply flows and adverse weather conditions impacting sales volumes, Radius Recycling has demonstrated resilience and adaptability. Recent productivity initiatives aim to reduce selling, general, and administrative expenses by 10%, alongside increasing production efficiencies, expected to yield $40 million in annual benefits.
Recent Financial Highlights:
- Revenue: Achieved $2.5 billion in fiscal 2014, reflecting robust market presence and operational efficiency.
- Global Reach: Positions in 25 states, Puerto Rico, and Western Canada, with deep-water export facilities expanding its market access.
- Strategic Initiatives: Focused on enhancing nonferrous production and expanding recycling services, positioning the company favorably against market headwinds.
Under the leadership of Tamara Lundgren, Chairman and CEO, Radius Recycling remains focused on cost control, operational efficiency, and strategic growth. The company's commitment to sustainability and low-carbon technologies aligns with global decarbonization trends, positioning Radius to capitalize on future market opportunities.
Partnerships and Projects: Radius continues to invest in advanced metal recovery technologies and expand its recycling platform, supporting its mission of promoting environmental sustainability and efficient resource use.
The company will report its financial results for the second quarter of fiscal 2024 on April 4, 2024, with a webcast conference call hosted by Tamara Lundgren and Stefano Gaggini, Senior Vice President and CFO, to discuss the results.
Radius Health, Inc. (Nasdaq: RDUS) reported continued growth in net new patients for TYMLOS-SC, with 1,326 new patients added in November 2020, marking an 8.0% increase from the previous average. The company is on track for a record quarter in TYMLOS-SC net revenue, surpassing the previous high of $56.7 million from Q4 2019. Additionally, Radius formed a research agreement with Massachusetts General Hospital to explore small molecules for musculoskeletal diseases. Peter Butler, MD, has been appointed as Head of Clinical Development for the abaloparatide program.
Radius Health (RDUS) reported Q3 2020 net sales of TYMLOS at $50.4 million, marking an 8% year-over-year increase. The total revenue for the quarter reached $77.8 million, supported by a significant rise in net new U.S. patients, increasing by 10% in October. The company maintains a cash balance of $126 million, ensuring operational funding for at least a year. However, Radius faced a net loss of $6.3 million for the quarter, though an improvement compared to last year's loss of $30 million. Japan's market launch of abaloparatide injection is on track for 2021.
Radius Health, Inc. (RDUS) announced significant clinical and business developments. Key highlights include the completion of enrollment in three pivotal Phase III clinical trials for osteoporosis treatments and a successful data presentation at the ASBMR meeting. The company also completed two business transactions, focusing on its oncology assets and repositioning its commercial strategy towards high-risk fracture patients. Additionally, operational improvements resulted in reduced sales territories and increased operational efficiency.
Radius Health (Nasdaq: RDUS) announced the release of its third quarter financial results on November 5, 2020, with a conference call scheduled at 8:30 a.m. ET. Investors can access the call via domestic and international dial-in numbers, with a replay available later the same day. Radius focuses on developing innovative endocrine therapeutics, including its FDA-approved product, TYMLOS, for postmenopausal women with osteoporosis. The company's pipeline includes investigational treatments for osteoporosis in men and hormone-receptor positive breast cancer.
Radius Health, Inc. (Nasdaq: RDUS) has appointed Peter A. Schwartzman as Vice President of the newly created Capital, Strategy, and Transactions (CST) Group. Schwartzman previously worked at Piney Lake Capital Management and has extensive experience in healthcare investments. The CST group will handle business development analysis, due diligence, and serve as a contact point for capital providers and investment banks. This strategic move aims to enhance Radius's financial modeling and business opportunities.
Radius Health has sold its second oncology asset, RAD140, to Ellipses Pharma, allowing the molecule to progress without financial risk to Radius. This divestment reinforces Radius's focus on its core business in innovative endocrine therapeutics. RAD140, a selective androgen receptor modulator, demonstrated clinical activity in a Phase 1a study involving postmenopausal women with advanced breast cancer. Radius is set to receive royalties as the program advances under Ellipses Pharma's management.
Radius Health and Menarini Group announced the successful completion of enrollment in the Phase 3 EMERALD trial of elacestrant, an oral Selective Estrogen Receptor Degrader (SERD) targeting postmenopausal individuals with ER+/HER2- advanced breast cancer. The trial reached its goal of 466 patients, including 220 with ESR1 mutations. The independent data monitoring committee recommended the trial continues without modification after reviewing a futility analysis. Final results, focusing on progression-free survival, are expected in the latter half of 2021.
Radius Health announced reaching the target enrollment milestone in the Phase 3 EMERALD trial of elacestrant, aimed at treating advanced breast cancer. The trial enrolled 466 patients, with 220 (47%) having an ESR1 mutation. An independent data monitoring committee recommended continuing the trial without modification after a futility analysis. Results assessing progression-free survival are expected in the second half of 2021. Both Radius and Menarini Group expressed enthusiasm over this milestone and its implications for future regulatory submissions.
Radius Health, Inc. announced the immediate resignation of Chief Financial Officer Jose (Pepe) Carmona, who played a pivotal role in the company's transition to a commercial entity. Dan Dolan has been appointed as Principal Financial and Accounting Officer, while Jim Chopas continues as Controller. The company also introduced a new Capital, Strategy, and Transactions (CST) group to enhance financial management and investor relations. This strategic reorganization aims to support Radius's growth and operational efficiency in the biopharmaceutical sector.
Radius Health announced presentations on abaloparatide-SC at the ASBMR 2020 Annual Virtual Meeting from September 11-15, highlighting significant findings.
Dr. Charles Morris emphasized notable results from a histomorphometry study, indicating strong bone formation in postmenopausal women with osteoporosis after 3 months of treatment.
The data will include details from the Phase III study in Japan, confirming its efficacy in high-risk fracture osteoporosis patients.
FAQ
What is the current stock price of Radius Recycling (RDUS)?
What is the market cap of Radius Recycling (RDUS)?
What is Radius Recycling, Inc.?
What does Radius Recycling do?
Where is Radius Recycling headquartered?
What are the key business units of Radius Recycling?
How has Radius Recycling performed financially?
What are the latest financial results for Radius Recycling?
What are Radius Recycling's strategic initiatives?
Who is the CEO of Radius Recycling?
How does Radius Recycling contribute to sustainability?
Where can I find more information about Radius Recycling?
